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doi:10.1Objective: To report the outcomes from a large multicenter cohort of neonates requiring extracorporeal mem-
brane oxygenation (ECMO) after stage 1 palliation for hypoplastic left heart syndrome.
Methods: Using data from the Extracorporeal Life Support Organization (2000–2009), we computed the sur-
vival to hospital discharge for neonates (age 30 days) supported with ECMO after stage 1 palliation for hypo-
plastic left heart syndrome. The factors associated with mortality were evaluated using multivariate logistic
regression analysis.
Results:Among 738 neonates, the survival ratewas 31%. Themedian age at cannulation was 7 days (interquartile
range, 4–11). Black race (odds ratio [OR], 2.0; 95% confidence interval [CI], 1.2–3.6), mechanical ventilation
before ECMO (>15–131 hours: OR, 1.6; 95%CI, 1.1–2.4;>131 hours: OR, 1.9; 95%CI, 1.3–2.9), use of positive
end expiratory pressure (>6–8 cm H2O: OR, 1.7; 95% CI, 1.1–2.7;>8 cm H2O: OR, 1.9; 95% CI, 1.2–3.1), and
longer ECMO duration (per day, OR, 1.2; 95% CI, 1.1–1.3) increased mortality. ECMO support for failure to
wean from cardiopulmonary bypass (OR, 1.6; 95% CI, 1.02–2.4) also decreased survival. ECMO complications,
including renal failure (OR, 1.9; 95% CI, 1.2–3.1), inotrope requirement (OR, 1.5; 95% CI, 1.1–2.1), myocardial
stun (OR, 3.2; 95% CI, 1.3–7.7), metabolic acidosis (OR, 2.9; 95% CI, 1.3–6.7), and neurologic injury (OR, 1.7;
95% CI, 1.1–2.6), during support also increased mortality.
Conclusions: Mortality for neonates with hypoplastic left heart syndrome supported with ECMO after stage 1
palliation is high. Longer ventilation before cannulation, longer support duration, and ECMO complications in-
creased mortality. (J Thorac Cardiovasc Surg 2012;144:1337-43)Extracorporeal membrane oxygenation (ECMO) is com-
monly used in neonates with refractory cardiopulmonary
failure after palliative surgery for single ventricle congeni-
tal heart disease, including hypoplastic left heart syndrome
(HLHS).1 Previous reports have indicated that 8% to 12%
of patients undergoing stage 1 palliation (S1P) require
postoperative ECMO, and ECMO use in patients with
HLHS is increasing.2,3 Despite the increasing use, the re-
ported survival to hospital discharge is variable and poor
(28%–64%).2,4,5 This wide variability in survival might re-
flect differences in patient selection, timing of ECMO de-
ployment, ECMO management, and experience among
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The Journal of Thoracic and Carand ECMO use in HLHS, the costs of ECMO, and the evo-
lution of mechanical circulatory support devices for chil-
dren, it is important to understand the ECMO outcomes
for infants supported with ECMO after S1P.
The purpose of the present study was to describe the us-
age trends, survival to hospital discharge, and factors asso-
ciated with mortality for neonates with HLHS supported
with ECMO after S1P using multicenter data reported to
the Extracorporeal Life Support Organization’s (ELSO)
data registry.METHODS
Data Source and Study Population
We retrospectively analyzed data obtained from the ELSO Registry for
neonates with HLHS supported with ECMO after S1P. The Registry
collects data on ECMO use from patients of all ages from 116 centers.1
Participating centers voluntarily report data to the registry using a standard-
ized data form. The data reported includes demographics, procedural in-
formation, pre-ECMO status, ECMO support details and complications,
and patient outcomes. HLHS anatomic variants and S1P shunt types are
not collected in the Registry. The data are reported to ELSO after approval
from each center’s institutional review board. A data user agreement al-
lows the release of limited de-identified data for research to member
centers.
The study population included all neonates (30 days of age at ECMO)
reported to the ELSO Registry from January 1, 2000, to December 31,
2009, with a primary admission diagnosis of HLHS (Internationaldiovascular Surgery c Volume 144, Number 6 1337
Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
ECMO ¼ extracorporeal membrane oxygenation
ELSO ¼ Extracorporeal Life Support
Organization
HLHS ¼ hypoplastic left heart syndrome
S1P ¼ stage 1 palliation
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DClassification of Diseases, 9th revision, code 746.7) and a primary proce-
dure code for S1P (Common Procedural Terminology code 33619). For pa-
tients with primary cardiac disease using ECMO after January 1, 2001, an
addendum (Cardiac Addendum) containing details of the cardiac surgical
procedure and cardiac indication for ECMO were also available for analy-
sis. The Committee on Clinical Investigation at Children’s Hospital Boston
approved the present study.
Data Categorization
Noncardiac abnormalities were categorized using International Clas-
sification of Diseases, 9th revision, codes for major structural abnormal-
ities including tracheo-esophageal fistula, cleft palate, urogenital
abnormalities, and musculoskeletal anomalies. The mode of ECMO
was dichotomized as venoarterial or other, including venovenous or
a combination of modes. Arterial cannulation sites were categorized as
aorta, right common carotid, or other, including left common carotid
and femoral artery sites. Venous cannulation sites were grouped into right
atrium or other, including right or left internal jugular or femoral veins.
The duration of mechanical ventilation before ECMO was the cumulative
duration of mechanical ventilation from endotracheal intubation to
ECMO deployment and included mechanical ventilator support in the
pre- and postoperative periods.
For patients with additional Cardiac Addendum data (n ¼ 506), the in-
dication for ECMO included low cardiac output, failure to wean from car-
diopulmonary bypass (CPB), and hypoxia. ECMO complications were
categorized using complication codes created by ELSO, as previously de-
scribed by Thiagarajan and colleagues.6 Data regarding the type of HLHS
and type of pulmonary blood flow established in the S1P procedure (Bla-
lock-Taussig shunt vs right ventricle to pulmonary artery conduit) were
not collected by the Registry and were not available for analysis.FIGURE 1. Neonatal hypoplastic left heart syndrome (HLHS) extraco
1338 The Journal of Thoracic and Cardiovascular SurStatistical Analysis
Survival was defined as survival to hospital discharge to home or to an-
other facility. The demographic, pre-ECMO, ECMO support, and compli-
cation data were compared between survivors and nonsurvivors. The
Mann-Whitney U test was used to compare continuous data, and the chi-
square test was used for categorical data. Fisher’s exact test was used
when the expected counts in more than 20% of cells was less than 5.
The data are presented as the median with interquartile ranges (25th to
75th percentile) or frequencies with percentages, unless specified other-
wise. For patients with multiple ECMO runs (n ¼ 28), only data from
the first run were analyzed. The trends in ECMO use and survival were
analyzed using the chi-square test for linear trend.
Three multivariate logistic regression models were created to explore
the factors associated with mortality. The candidate variables for inclusion
were selected from the bivariate analysis based on aP value of .1, entered
into the regressionmodel using a forward-selection procedure, and retained
if their adjusted P value was  .05. A continuous variable retained in
a model was evaluated for a linear association with mortality and only re-
tained as a continuous variable if this assumption was satisfied. Variables
not meeting the criteria for linearity were divided into categories according
to their distribution (eg, trichotomized) and refitted in the model as categor-
ical variables. The data were analyzed using SPSS, version 18.0 (SPSS,
Chicago, Ill) and Stata, version 11.0 (StataCorp, College Station, Tex).
RESULTS
Study Population
A total of 738 neonates with HLHS (26% of all neonatal
cardiac ECMO runs) underwent 767 ECMO runs after S1P
and were reported to the ELSO Registry from 2000 to 2009.
The median age was 7 days (interquartile range, 4–11) at
cannulation, and themedianweight was 3.1 kg (interquartile
range, 2.69–3.4); 36 (5%) had noncardiac anomalies, and
237 (32%) had had cardiac arrest before ECMO use. Ve-
noarterial ECMO (n ¼ 711, 96%) was the most commonly
used support mode. The ECMO indication included cardiac
(n ¼ 624, 85%), supporting cardiopulmonary resuscitation
(extracorporeal cardiopulmonary resuscitation; n ¼ 105,
14%), and respiratory (n ¼ 9, 1%). Also, 28 patients
(4%) requiredmore than 1 ECMO run, with only 1 survivor.rporeal membrane oxygenation (ECMO) use and survival trends.
gery c December 2012
TABLE 1. Demographic and pre-ECMO features of survivors and
nonsurvivors
Variable
Survivors
(n ¼ 226)
Nonsurvivors
(n ¼ 512)
P
value
Age (d) .68
Median 7 7
Interquartile range 5–10 4–11
Male gender 142 (63) 302 (59) .51
Weight (kg) .03*
Median 3.2 3.0
Interquartile range 2.8–3.4 2.6–3.4
Race .02*
White 159 (70) 312 (61)
Black 20 (9) 85 (17)
Other 43 (19) 109 (21)
Noncardiac anomalies 10 (4) 26 (5) .70
Pre-ECMO arterial blood gas values
pHy .24
Median 7.29 7.28
Interquartile range 7.21–7.37 7.17–7.39
Partial pressure of carbon dioxide
(mm Hg)y
.73
Median 47 46
Interquartile range 41–57 38–58
Partial pressure of oxygen
(mm Hg)y
.52
Median 37 39
Interquartile range 30–49 29–53
Standardized bicarbonate
(mmol/L)y
.02*
Median 23 21.9
Interquartile range 20–26 18–25
Peripheral oxygen saturation (%)y .49
Median 70 67
Interquartile range 57–81 51–85
Fraction of inspired oxygen .87
Median 0.96 0.94
Interquartile range 0.35–1.00 0.35–1.00
Pre-ECMO status and support
Bicarbonate administration 79 (35) 155 (30) .21
Neuromuscular blockade 123 (54) 294 (57) .45
Inotrope requirement 188 (83) 442 (86) .27
Temporary pacemaker use 18 (8) 47 (9) .59
Cardiac arrest 74 (33) 163 (32) .81
High-frequency oscillatory
ventilation
3 (1) 11 (2) .33
Inhaled nitric oxide 43 (19) 110 (22) .45
Ventilation duration before
ECMO (h)
<.001*
Median 27 73
Interquartile range 7.5–139.5 13–175.5
15 98 (43) 145 (28) .001*
>15–131 65 (29) 172 (29)
>131 58 (26) 180 (26)
Missing 5 (2) 15 (2)
(Continued)
TABLE 1. Continued
Variable
Survivors
(n ¼ 226)
Nonsurvivors
(n ¼ 512)
P
value
Year of ECMO .09
2000–2001 25 (11) 72 (14)
2002–2003 47 (21) 98 (19)
2004–2005 30 (13) 104 (20)
2006–2007 72 (32) 134 (26)
2008–2009 52 (23) 104 (20)
Heart transplantation 2 (1) 8 (2) .37
Data presented as numbers, with percentages in parentheses, unless otherwise noted.
ECMO, Extracorporeal membrane oxygenation. *Statistically significant. yVariables
with>10%missing data (pH, n¼ 119; peripheral oxygen saturation, n¼ 190; partial
pressure of carbon dioxide, n¼ 120; partial pressure of oxygen, n¼ 121; standardized
bicarbonate, n ¼ 182).
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DTen patients underwent cardiac transplantation, with two
survivors. Overall, 438 (59%) were weaned from ECMO,
and 226 patients (31%) survived to hospital discharge.
The trends in cardiac ECMO use and survival are shown
in Figure 1. A significant increase in the number of patients
supported with ECMO after S1P was seen during the study
period (P ¼ .02); however, no improvement was seen in
survival (P ¼ .2).
ECMO Survivors Versus Nonsurvivors
Demographic and pre-ECMO data. The demographic
and pre-ECMO features of survivors and nonsurvivors are
listed in Table 1. The nonsurvivor group had significantly
lower weight, a greater percentage of infants of black
race, lower serum bicarbonate values, and a longer duration
of mechanical ventilation before ECMO cannulation com-
pared with the survivor group.
ECMO-related factors. The ECMO-related features of
the survivors and nonsurvivors are listed in Table 2. Nonsur-
vivors required greater positive end-expiratory pressure at
24 hours after ECMO deployment and longer ECMO
duration.
ECMO complications. The ECMO complications in sur-
vivors and nonsurvivors are also listed in Table 2. Nonsurvi-
vors had a greater frequency of mechanical complications,
surgical bleeding, disseminated intravascular coagulation,
neurologic injury, renal failure, cardiopulmonary resuscita-
tion, metabolic acidosis (arterial blood pH<7.2), need for
inotropic support, cardiac arrhythmias, myocardial stun,
pulmonary complications (ie, pneumothorax or pulmonary
hemorrhage), culture-proven infection, and hypoglycemia
during ECMO support.
Cardiac Addendum. The Cardiac Addendum variables in
survivors and nonsurvivors are listed in Table 3. The propor-
tion of neonates requiring ECMO for failure to wean from
CPB was greater in the nonsurvivor group. The duration
of CPB, aortic crossclamp time, and interval from surgery
to ECMO cannulation were longer in the nonsurvivors
than in the survivors.diovascular Surgery c Volume 144, Number 6 1339
TABLE 2. ECMO variables and complications in survivors and
nonsurvivors
Variable
Survivors
(n ¼ 226)
Nonsurvivors
(n ¼ 512)
P
value
Support type .67
ECPR 34 (15) 71 (14)
Cardiac or respiratory 192 (85) 441 (86)
ECMO mode (venoarterial) 218 (97) 493 (96) .91
Arterial cannulation site .88
Aorta 178 (79) 388 (76)
Right common carotid artery 36 (16) 94 (18)
Venous cannulation site .27
Right atrium 185 (84) 397 (80)
ECMO flow at 24 h (mL/kg/min) .20
Median 131 136
Interquartile range 100–169 109–173
Ventilator type during ECMO .10
Conventional 143 (63) 292 (57)
HFOVor other 0 (0) 6 (1)
Ventilator breath rate .05*
Median 15 14
Interquartile range 10–22 10–20
Fraction of inspired oxygen (%) .28
Median 30 25
Interquartile range 21–40 21–40
Positive end expiratory pressure
(cm H2O)
.004*
Median 5 6
Interquartile range 5–8 5–8
Duration of ECMO duration (h) <.001*
Median 71 122
Interquartile range 47–118 69–189
Multiple ECMO runs 1 (0.4) 27 (5.3) <.001*
Mechanical complications
Circuit complications 16 (7) 86 (17) <.001*
Air embolism 6 (3) 20 (4) .40
Circuit thrombosis 45 (20) 168 (33) <.001*
Complications
Surgical bleeding 79 (35) 239 (48) .003*
Disseminated intravascular
coagulation
2 (1) 21 (4) .02*
Neurologic injury 33 (15) 132 (26) <.001*
Renal failure 24 (11) 126 (25) <.001*
CPR during ECMO 1 (0.5) 19 (4) .01*
Arterial blood pH<7.2 during
ECMO
7 (3) 57 (11) <.001*
Need for inotropes during ECMO 135 (60) 368 (72) <.001*
Myocardial stun during ECMO 6 (3) 55 (11) <.001*
Arrhythmias during ECMO 20 (9) 88 (17) .003*
Tamponade during ECMO 10 (4) 41 (8) .08
Respiratory complicationsy 3 (1) 35 (7) <.001*
(Continued)
TABLE 2. Continued
Variable
Survivors
(n ¼ 226)
Nonsurvivors
(n ¼ 512)
P
value
Gastrointestinal hemorrhage 1 (0.5) 6 (1) .40
Hyperbilirubinemiaz 7 (3) 33 (6) .06
Culture proven infection 8 (4) 42 (8) .02*
Hypoglycemia (<40 mg/dL) 0 19 (4) .003*
Hyperglycemia (>240 mg/dL) 37 (16) 88 (17) .80
Data presented as numbers, with percentages in parentheses, unless otherwise noted.
ECMO, Extracorporeal membrane oxygenation; ECPR, extracorporeal cardiopulmo-
nary resuscitation;HFOV, high-frequency oscillatory ventilation; CPR, cardiopulmo-
nary resuscitation. *Statistically significant. yRespiratory complications included
pneumothorax or pulmonary hemorrhage. zHyperbilirubinemia indicated by total se-
rum bilirubin of>15 mg/dL or direct>2 mg/dL.
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DFactors associated with mortality. Three multivariate re-
gression models of factors associated with mortality are
listed in Table 4. Model 1 evaluated the demographic,
pre-ECMO, and ECMO variables. Black race, longer me-
chanical ventilation duration before ECMO (>15 hours),1340 The Journal of Thoracic and Cardiovascular Surthe need for greater positive end-expiratory pressure (>6
cm H2O) at 24 hours after ECMO deployment, and longer
ECMO duration were associated with increased mortality.
The use of multiple ECMO runs was not considered for in-
clusion in the model, because only 1 patient survived.
Model 2 identified the ECMO complications associated
with mortality. After adjusting for the duration of ECMO
support, the continued need for inotropic support, occur-
rence of myocardial stun, metabolic acidosis, neurologic in-
jury, and renal failure during ECMO increased the odds of
mortality. Hypoglycemia was not included in the multivar-
iate analysis because there were no survivors. The associa-
tion between ECMO duration and complications using
interaction terms and mortality was not tested.
Model 3 fitted the qualifyingCardiacAddendumvariables
into a model containing variables retained in Model 1. Lon-
germechanical ventilation before ECMO, longer ECMOdu-
ration, and ECMO for failure to separate from CPB were all
associated with increased mortality; however, CPB duration
and interval from surgery to ECMO initiation were not.
Distribution of nonsurvivors by ECMO duration. Fig-
ure 2 shows the distribution of survivors and nonsurvivors
stratified by ECMO duration. There were few survivors
after 9 days of ECMO (Figure 2, A). Figure 2, B shows
the proportion of survivors and nonsurvivors by day of
ECMO. The proportion of nonsurvivors was greater imme-
diately after ECMO deployment and after 5 days of ECMO
support.
DISCUSSION
In 738 neonates with HLHS supported with ECMO in
the postoperative period after S1P, the overall survival to
hospital discharge was poor (31%). Despite increasing
ECMO use after S1P during the 10-year period, survival
has not improved. We found increased mortality in those
who required longer mechanical ventilation before
ECMO, those with lung injury, reflected by the use of
greater positive end-expiratory pressure within 24 hours
of ECMO deployment, those who were unable to wean
from CPB after S1P, and those who needed longergery c December 2012
TABLE 4. Multivariate regression models: predictors of mortality in
S1P HLHS neonates requiring ECMO
Variable OR 95% CI
P
value
Model 1: demographic and ECMO support
Race
White 1.0
Black 2.0 1.2–3.6 .01*
Other 1.4 0.9–2.1 .16
Ventilation duration before ECMO (h)
15 1.0
>15–131 1.6 1.1–2.4 .02*
>131 1.9 1.3–2.9 .003*
Missing 1.2 0.4–3.7 .8
PEEP at 24 h after ECMO onset (cm H2O)
5 1.0
>5–6 1.2 0.7–2.2 .6
>6–8 1.7 1.1–2.7 .02*
>8 1.9 1.2–3.1 .02*
Missing 3.1 1.7–5.9 .001
ECMO duration (d) 1.2 1.1–1.3 <.001*
Model 2: ECMO Complications
ECMO duration (d) 1.2 1.1–1.23 <.001*
Inotrope use 1.5 1.1–2.1 .03*
Myocardial stun 3.2 1.3–7.7 .01*
Blood pH<7.2 2.9 1.3–6.7 .01*
Neurologic injury 1.7 1.1–2.6 .02*
Renal failure 1.9 1.2–3.1 .01*
Model 3: Cardiac Addendum
Ventilation duration before ECMO (h)
15 1.0
>15–131 1.7 1.1–2.7 .03*
>131 3.1 1.8–5.2 <.001*
Failure to wean cardiopulmonary bypass 1.6 1.02–2.4 .04*
ECMO duration (d) 1.3 1.2–1.35 <.001*
Model 1, n¼ 728; area under the curve, 0.70; model 2, n¼ 738; area under the curve,
0.73; and model 3, n ¼ 494; area under the curve, 0. HLHS, Hypoplastic left heart
syndrome; OR, odds ratio; CI, confidence interval; ECMO, extracorporeal membrane
oxygenation; PEEP, positive end expiratory pressure. *Statistically significant.
TABLE 3. Cardiac Addendum variables in survivors and
nonsurvivors
Variable
Survivors
(n ¼ 155)
Nonsurvivors
(n ¼ 351)
P
value
Indication for ECMO*
Low cardiac output 107 (69) 241 (69) .93
Failure to wean from CPB 53 (34) 156 (44) .03y
Hypoxia 37 (24) 78 (22) .68
Cardiopulmonary bypass time (min) <.001y
Median 156 186
Interquartile range 126–201 138–251
Aortic crossclamp time (min)z .04y
Median 58 62
Interquartile range 43–72 47–83
Interval from surgery to
cannulation (h)z
.04y
Median 9 11
Interquartile range 5–21.3 7–23
Data presented as numbers, with percentages in parentheses. ECMO, Extracorporeal
membrane oxygenation;CPB, cardiopulmonary bypass. *Categories not mutually ex-
clusive. yStatistically significant. zVariables with>10% missing data (crossclamp
time, n ¼ 70).
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DECMO support. The occurrence of ECMO complications
also decreased survival. Poor outcomes despite the in-
creasing use of ECMO in this population suggest a need
for careful evaluation of the use of ECMO and exploration
of other mechanical support devices for this population.
Furthermore, our findings suggest that careful patient se-
lection and minimizing ECMO complications might help
improve survival in this population.
This survival rate reported for ECMO use in patients
with HLHS after S1P is similar to the overall survival
rate of 38% reported for all cardiac ECMO use in neonates
with congenital heart disease by the ELSO Registry
(2000–2009)7 but lower than those reported for ECMO
use after other operations such as arterial switch (43%).1
The interpretation of the low survival rate in this popula-
tion must take into account the inherent high-risk nature
of S1P for HLHS and that many patients supported with
ECMO have exhausted all other therapies and face immi-
nent mortality. The lower survival rate in the present anal-
ysis compared with the greater survival rates reported by
single-center reports might reflect a publication bias, as
well as differences in the timing of ECMO deployment,
ECMO management, and experience between centers, re-
sulting in improved outcomes in some centers compared
with others.
Hoskote and colleagues4 in their report of ECMO use af-
ter palliative surgery for single ventricle lesions suggested
that elective deployment before complications such as car-
diac arrest might improve the outcomes. Allan and col-
leagues2 in their study of ECMO outcomes for single
ventricle patients reported improved outcomes when
ECMO was used to support a reversible event such as acute
Blalock-Taussig shunt obstruction than for support ofThe Journal of Thoracic and Carmyocardial dysfunction. These studies indicate that both
early deployment and patient selection might be important
determinants of outcomes in these patients. Morris and col-
leagues8 showed, in 137 patients with congenital heart dis-
ease supported with ECMO, that prolonged mechanical
ventilation before ECMO was associated with increased
mortality. Similarly, we found that thosewho required a lon-
ger duration of mechanical ventilation before ECMO had
greater odds of mortality. The need for longer mechanical
ventilation might be a surrogate for both the severity of ill-
ness or possibly irreversible cardiopulmonary failure and
thus might decrease the survival outcomes. We found that
the cumulative proportion of nonsurvivors was greater at
ECMO initiation and again after 5 days of ECMO support
(Figure 2, B). In addition to the risks inherent to the techni-
cal aspects of ECMO cannulation, surgical bleeding, and
bleeding owing to anticoagulant use during ECMO, itsdiovascular Surgery c Volume 144, Number 6 1341
FIGURE 2. Distribution of survivors and nonsurvivors according to extracorporeal membrane oxygenation (ECMO) duration. A, Number of survivors and
nonsurvivors stratified by day of ECMO. B, Cumulative proportion of survivors and nonsurvivors stratified by day of ECMO.
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Duse after the onset of irreversible end-organ injury might
also lead to early mortality with withdrawal of ECMO ow-
ing to a lack of early improvement or even futility. The
causes of death and level of illness before ECMO deploy-
ment could not be precisely evaluated from our data.
From our analysis and the existing knowledge in this area,
we speculate that neonates placed on ECMO early after
S1P, before the onset of irreversible end-organ injury, and
those who have a reversible cause for cardiorespiratory fail-
ure (eg, Blalock-Taussig occlusion owing to shunt thrombo-
sis) might be best suited for support with ECMO. We have
also shown that few patients survived after 9 days of ECMO
support (Figure 2, A). Thus, in addition to careful patient
selection and ECMO deployment, investigation and correc-
tion of potentially reversible lesions after S1P (eg, atrioven-
tricular regurgitation) might allow early weaning of ECMO
support and might be important for improving survival. Al-
ternatively, this period might serve as a guide for medical1342 The Journal of Thoracic and Cardiovascular Surdecision making such as listing for cardiac transplantation
or prognostication.
Ravishankar and colleagues5 in their report of ECMO use
after S1P showed that a need for ECMO less than 24 hours
after surgery was associated with decreased survival. Al-
though they did not separately evaluate failure to wean
from CPB, it is possible that some of their patients had
ECMO initiated for this indication. Although we did not
find an independent relationship between the interval
from surgery to ECMO cannulation and mortality, we found
ECMO initiated for failure to wean off CPB was associated
with increased mortality. We speculate that these patients
who failed to wean from CPB after S1P might have sus-
tained irreversible myocardial injury during the course of
their operation and were unlikely to survive despite
ECMO support. We found that mortality was increased in
patients of black race, supporting previously noted racial
differences in ECMO outcomes.8 The reasons for thisgery c December 2012
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Dassociation are poorly understood and cannot be easily eval-
uated from our data. Similar to other reports, we found that
ECMO complications increased mortality in our study pop-
ulation. Although some complications might be unavoid-
able, meticulous attention to limiting complications might
improve survival. Finally, we observed a 28% mortality
rate in patients successfully weaned from ECMO. The rea-
sons for mortality after successful ECMO weaning could
not be evaluated from these data but should be the focus
of future research.
Our results are limited by the retrospective design and
use of a multicenter database. The data reported to the
ELSO Registry are not specific for the analysis of
ECMO outcomes for patients with HLHS after S1P.
Thus, important factors influencing mortality might have
been missed. For example, the details of HLHS anatomic
variants and shunt type used in S1P were not available
for analysis. The missing values for many variables pre-
cluded their inclusion in the multivariate analysis. Other
important information such as reporting center demo-
graphics and practice variability among centers regarding
the use and treatment of patients on ECMOwere not avail-
able for analysis because data user agreements between re-
porting centers and ELSO precluded the release of such
information. Thus, the influence of important variables
such as center size, volume, and ECMO management on
outcomes could not be evaluated; this should be consid-
ered an important limitation of the present data. Finally,
long-term survival, neurologic and functional outcomes,
and quality of life measures for survivors were not
available.The Journal of Thoracic and CarCONCLUSIONS
ECMO has been increasingly used to support patients
with HLHS after S1P; however, mortality has remained
high. Careful patient selection, the early deployment of
ECMO, and the careful management of ECMO to avoid
complications might help improve survival. Finally, future
research exploring other strategies such as early consider-
ation for transplantation and support with newer mechanical
circulatory assist devices should be studied to improve the
outcomes in this high-risk population.
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